Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Rituximab 6ibrutinib 4venetoclax 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Cyclophosphamide 2Bortezomib 2Bendamustine Hydrochloride 2selinexor 1loncastuximab tesirine 1ixazomib 1carfilzomib 1Valganciclovir 1Valacyclovir 1Therapeutics 1Tacrolimus 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Lenalidomide 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Waldenstrom Macroglobulinemia × Pharmacogenomic Testing × Clear all
NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡